It's hard to fault the FDA commissioner for his even-handed treatment of the two drug industries—branded vs. generic—and the competing social imperatives they stand for: new drug research and affordability.
In recent speeches, Mark McClellan, MD, PhD, has been making the branded industry's case both for higher drug reimbursement from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?